Abstract: This disclosure relates to the design of E. coli mutated FimH polypeptides that result in improved biochemical properties and immunogenicity, compositions comprising such polypeptides, and uses thereof.

Abstract: This invention relates to compositions that include a polypeptide derived from E. coli or a fragment thereof; and modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof, and methods of use thereof.

Abstract: The invention concerns a method for relieving idiopathic ocular pain by administering an effective amount of a fluid composition comprising hyaluronic acid, a hyaluronic acid analogue, or a combination thereof, to the eye of a human or non-human animal subject, wherein the fluid composition is administered after onset of the idiopathic ocular pain and in the absence of detectable signs known to cause ocular pain.

Abstract: The invention relates to RNA molecules encoding an E. coli fimbrial H antigen (FimH). The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the prevention of E. coli infection, including urinary tract infection.

Abstract: This invention relates to compositions that include a polypeptide derived from E. coli or a fragment thereof; and modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof, and methods of use thereof.

Abstract: This invention provides a recombinant Escherichia coli (E. coli) host cell for producing a Klebsiella pneumoniae (K. pneumoniae) O-antigen, wherein the E. coli host cell comprises a polynucleotide encoding the K. pneumoniae O-antigen, including methods of producing and purifying the K. pneumoniae O-antigen.

Abstract: The present invention concerns the use of very high molecular weight hyaluronic acid (HMWHA) as a transporting vehicle for bioactive agents, such as ophthalmic drugs and other active pharmaceutical ingredients (API), with minimized side effects. An aspect of the invention includes an ophthalmic drug-delivery system (ODS) comprising HMWHA fluid and a bioactive agent, wherein the hyaluronic acid has an intrinsic viscosity of at least 2.5 m3/kg, and the HMWHA fluid is capable of transporting the bioactive agent into the eye; a method for delivering a bioactive agent into the eye; a method for treating, preventing, and/or delaying the onset or recurrence of an eye disorder in a human or animal subject; and a kit useful for carrying out the methods of the invention.

Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

Abstract: The invention concerns a method for treating nerve damage or loss in the cornea of an eye (corneal nerve damage or loss) of a human or non-human animal subject, comprising topically administering a fluid comprising high molecular weight hyaluronic acid (HMWHA) to the ocular surface of the eye, wherein the hyaluronic acid has an intrinsic viscosity of at least 2.5 m3/kg.

Abstract: The present invention concerns ophthalmic compositions comprising a combination of hyaluronic acid (HA) as a vehicle, and one or more prostaglandin analogues, such as latanoprost, as an active pharmaceutical ingredient (API), wherein the HA acts as a transporting vehicle (transporter) of the prostaglandin analogue into the eye. The invention also includes methods for the use of such ophthalmic compositions for reduction of intraocular pressure to treat, prevent, and/or delay the onset or recurrence of ocular hypertension and glaucoma. The ophthalmic compositions of the invention have improved stability, improved API solubility, and improved efficacy in reducing intraocular pressure.

Abstract: This disclosure relates to the design of E. coli mutated FimH polypeptides that result in improved biochemical properties and immunogenicity, compositions comprising such polypeptides, and uses thereof.

Abstract: This invention relates to compositions that include a polypeptide derived from E. coli or a fragment thereof; and modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof, and methods of use thereof.

Abstract: The invention concerns a method for relieving idiopathic ocular pain by administering an effective amount of a fluid composition comprising hyaluronic acid, a hyaluronic acid analogue, or a combination thereof, to the eye of a human or non-human animal subject, wherein the fluid composition is administered after onset of the idiopathic ocular pain and in the absence of detectable signs known to cause ocular pain.

Abstract: The invention concerns a method for restoring or replenishing hyaluronic acid at an epithelial surface of a subject, comprising topically administering a composition to the epithelial surface of the subject, wherein the composition comprises high molecular weight hyaluronic acid, high molecular weight hyaluronic acid analogue, or a combination thereof, and wherein the epithelial surface has a deficiency in the amount or function of hyaluronic acid.

Abstract: The invention concerns a method for reducing, preventing, or delaying the onset of severe ocular surface disease, or preventing or delaying the progression of mild or moderate ocular surface disease to severe ocular surface disease, by topically administering a fluid comprising high molecular weight hyaluronic acid to the ocular surface of the eye of a human or non-human animal subject, wherein the hyaluronic acid has an intrinsic viscosity of >2.5 m3/kg and a concentration of <0.2% w/v.

Abstract: The invention concerns a method for reducing or delaying the onset of irritation, discomfort, inflammation (acute or chronic), and/or an immune response at the ocular surface by topically administering a fluid comprising high molecular weight hyaluronic acid to the ocular surface of the eye of a human or non-human animal subject, wherein the hyaluronic acid has an intrinsic viscosity of >2.5 m3/hg and a concentration of <0.2% w/v.

Abstract: A novel graphical interface and input method is provided. In certain implementations, a touch screen interface is provided with a plurality of icons that each represent seats around a table in a restaurant. Each icon is associated with a unique account. Accounts can be easily merged and split by using touch and swipe interfaces with the icons.

Abstract: A novel graphical interface and input method is provided. In certain implementations, a touch screen interface is provided with a plurality of icons that each represent seats around a table in a restaurant. Each icon is associated with a unique account. Accounts can be easily merged and split by using touch and swipe interfaces with the icons.

Abstract: A multi-piston motor/pump is disclosed particularly useful for air motor applications incorporating a cylinder block having a plurality of radially extending pistons and cylinders. Each cylinder is provided with a bronze insert at the top of the cylinder having an intake and exhaust port therein. Rotary valves are mounted on an output shaft and include axial flanges having openings therein that align with the input or exhaust openings in each cylinder. As the rotary valves rotate, the openings therein sequentially align with the input/exhaust ports provided in the bronze inserts such that air or fluid entering each cylinder enters axially of the cylinder. A center mounting plate is secured to the cylinder block and separates the input ports from the exhaust ports to enable fluid flow into the input ports and exhaust from the exhaust ports while isolating each port from the adjacent port in each cylinder.

Abstract: A push-push type fluid pressure actuated motor has one or more radial opposed cylinder sets each having a pair of pistons, a connecting rod, and a Scotch-yoke connection to a crankshaft. An intake rotor valve at one face of the cylinder block and an exhaust rotor valve at an opposite face of the cylinder block are mounted on and rotate with the crankshaft. The rotor valves admit pressurized fluid to the cylinder and allow discharge of spent fluid from the cylinders.